Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic Diseases

about

Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic Diseases

Item

http://www.wikidata.org/entity/Q38711151

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Rare Cyclophosphamide-Induced ...... lation with Rheumatic Diseases

@en

type

Item

label

Rare Cyclophosphamide-Induced ...... lation with Rheumatic Diseases

@en

prefLabel

Rare Cyclophosphamide-Induced ...... lation with Rheumatic Diseases

@en

P1476

Rare Cyclophosphamide-Induced ...... lation with Rheumatic Diseases

@en

P2093

Donging Chen

http://www.w3.org/2001/XMLSchema#string

Fan Lian

http://www.w3.org/2001/XMLSchema#string

Jun Zhou

http://www.w3.org/2001/XMLSchema#string

Liuqin Liang

http://www.w3.org/2001/XMLSchema#string

Xiaodong Wang

http://www.w3.org/2001/XMLSchema#string

Zheng Yang

http://www.w3.org/2001/XMLSchema#string

Zhongping Zhan

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.

Cyclophosphamide versus placebo in scleroderma lung disease.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.

Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus

Clinical pharmacokinetics of cyclophosphamide.

EULAR recommendations for the management of primary small and medium vessel vasculitis.

Using cyclophosphamide in inflammatory rheumatic diseases.

P2888

s40801-017-0112-y

P31

scholarly article

P356

10.1007/S40801-017-0112-Y

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1086126707

http://www.w3.org/2001/XMLSchema#string

P698

28646351

http://www.w3.org/2001/XMLSchema#string

P932

5567457

http://www.w3.org/2001/XMLSchema#string